BioSpace News Archive

Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.

Cytokinetics is discontinuing the Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis after its candidate reldesemtiv failed a planned interim analysis, the company announced Friday.

BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates.

In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.

Sensible Biotechnologies, an early stage biotechnology company, announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.

OpGen, Inc. reported that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant.

Theratechnologies Inc. announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12, 2023.

Kodiak Sciences Inc. (Nasdaq: KOD) announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak’s Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic.

SWK Holdings Corporation, a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2022.